Investigation Report on China's Voriconazole Market 2021-2025
Request Sample
Pre-order Enquiry
Request Customization
Check Discounts
Description
Voriconazole is used to treat progressive, potentially life-threatening fungal infections. Its product was developed by Pfizer. It was approved in China in 2004. By 2020, there are 11 manufacturers of Voriconazole in the Chinese market, of which Pfizer has the largest market share.
According to Researcher analysis, the sales of Voriconazole have grown steadily from 2016 to 2019. In 2020, its sales fell by 20.41%, from CNY1.888 billion in 2019 to CNY1.503 billion in 2020. The main reason is that the Covid-19 epidemic has affected the hospital's overall diagnosis and treatment business, resulting in a decline in its sales. The CAGR of Voriconazole in the Chinese market from 2016 to 2020 is 2.68%.
According to Researcher analysis, with the effective alleviation of the Covid-19 epidemic from 2021 to 2025, the sales of Voriconazole will have a restorative growth. In addition, there are 9 companies that have applied to enter the Chinese Voriconazole market in 2020. The price of Voriconazole will decline and the sales and sales volume have the potential for growth with the addition of new manufacturers. In addition, Voriconazole is used for various fungal infections and the number of specific indications is likely to increase, so its sales volume and sales still have the potential for increase.
Topics Covered:
-The impact of COVID-19 on China's Voriconazole market
- Sales value of China's Voriconazole 2016-2020
- Competitive landscape of China's Voriconazole market
- Prices of Voriconazole in China
- Prices of Voriconazole in China by regions and manufacturers
- Analysis of factors affecting the development of China's Voriconazole market
- Prospect of China's Voriconazole market from 2021 to 2025
Voriconazole is used to treat progressive, potentially life-threatening fungal infections. Its product was developed by Pfizer. It was approved in China in 2004. By 2020, there are 11 manufacturers of Voriconazole in the Chinese market, of which Pfizer has the largest market share.
According to Researcher analysis, the sales of Voriconazole have grown steadily from 2016 to 2019. In 2020, its sales fell by 20.41%, from CNY1.888 billion in 2019 to CNY1.503 billion in 2020. The main reason is that the Covid-19 epidemic has affected the hospital's overall diagnosis and treatment business, resulting in a decline in its sales. The CAGR of Voriconazole in the Chinese market from 2016 to 2020 is 2.68%.
According to Researcher analysis, with the effective alleviation of the Covid-19 epidemic from 2021 to 2025, the sales of Voriconazole will have a restorative growth. In addition, there are 9 companies that have applied to enter the Chinese Voriconazole market in 2020. The price of Voriconazole will decline and the sales and sales volume have the potential for growth with the addition of new manufacturers. In addition, Voriconazole is used for various fungal infections and the number of specific indications is likely to increase, so its sales volume and sales still have the potential for increase.
Topics Covered:
-The impact of COVID-19 on China's Voriconazole market
- Sales value of China's Voriconazole 2016-2020
- Competitive landscape of China's Voriconazole market
- Prices of Voriconazole in China
- Prices of Voriconazole in China by regions and manufacturers
- Analysis of factors affecting the development of China's Voriconazole market
- Prospect of China's Voriconazole market from 2021 to 2025
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Details
CRI-18360560
28-May-2021
50
28-May-2021
50
License
